Asia Pacific RNA Based Therapeutic Market Size, Share & Industry Trends Analysis Report By Type (RNA Antisense and RNA Interference (RNAi)), By Application, By End User, By Country, Historical Data and Growth Forecast, 2021 - 2027
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the Asia Pacific RNA Based Therapeutic Market
Market Report Description
The Asia Pacific RNA Based Therapeutic Market would witness market growth of 15.6% CAGR during the forecast period (2021-2027).
RNA-based biopharmaceuticals, which include vaccines and treatments, are a relatively new class of medicine. These biopharmaceuticals are preventive medicines that are used to treat a variety of rare and chronic diseases, such as cardiovascular disease, TB, diabetes, and cancer. The primary goal of RNA therapies is to develop an effective treatment for rare diseases and other unmet medical needs. This is a research-based area, and technological advancements are expected to increase the global RNA-based medicines and vaccines market during the forecasting period.
In addition, in upcoming years, the development of numerous potential technologies such as RNA interference technology, SMaRT technology, and antisense technology is anticipated to offer significant growth possibilities for the worldwide RNA-based therapies and vaccines market.
The market for RNA-based therapeutics and vaccines in Japan is the largest in the Asia Pacific, owing to the growing importance of customized medicine. In addition, the high frequency of infectious diseases in the Asia Pacific is likely to create significant potential for RNA-based therapeutics and vaccines. The rising population of the countries that comes under APAC such as India and China, plays a major role in accelerating the demand for RNA-based therapeutic across APAC.
In addition, these countries are under a developing phase and going under constant enhancements and developments rapidly. With these developments, the healthcare infrastructure of the region is constantly growing stronger.
The China market dominated the Asia Pacific RNA Based Therapeutic Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $685.8 million by 2027. The Japan market is exhibiting a CAGR of 15% during (2021 - 2027). Additionally, The India market would witness CAGR of 16.4% during (2021 - 2027).
Based on Type, the market is segmented into RNA Antisense and RNA Interference (RNAi). Based on Application, the market is segmented into Genetic disorders and Auto immune disorders. Based on End User, the market is segmented into Research Institutes and Hospitals & Clinics. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals, Inc., Benitec Biopharma, Inc., Alnylam Pharmaceuticals, Inc., Sanofi S.A. (Sanofi Genzyme), Biogen, Inc., Gradalis, Inc., Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., and Silence Therapeutics Plc.
Scope of the Study
Market Segments Covered in the Report:
- RNA Antisense
- RNA Interference (RNAi)
- Genetic disorders
- Auto immune disorders
By End User
- Research Institutes
- Hospitals & Clinics
- South Korea
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Arbutus Biopharma Corporation
- Arrowhead Pharmaceuticals, Inc.
- Benitec Biopharma, Inc.
- Alnylam Pharmaceuticals, Inc.
- Sanofi S.A. (Sanofi Genzyme)
- Biogen, Inc.
- Gradalis, Inc.
- Ionis Pharmaceuticals, Inc.
- Sarepta Therapeutics, Inc.
- Silence Therapeutics Plc
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free